Wiley Bros.-aintree Capital »

Bioxcel Therapeutics shares owned by Wiley Bros.-aintree Capital

Quarter-by-quarter ownership of Bioxcel Therapeutics (BTAI) shares owned by Wiley Bros.-aintree Capital from 13F filings

Historical chart of Wiley Bros.-aintree Capital investment in Bioxcel Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Bioxcel Therapeutics held by Wiley Bros.-aintree Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Bioxcel Therapeutics by Wiley Bros.-aintree Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $108k 81k 1.34

More positions owned by Wiley Bros.-aintree Capital

Apple (AAPL)
Ishares Tr Core S&p500 Etf (IVV)
Ishares Tr Core S&p Mcp Etf (IJH)
Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)
Ishares Tr Core Us Aggbd Et (AGG)
Dimensional Etf Trust Intl Core Eqt Mk (DFAI)
Ishares Tr Core Msci Eafe (IEFA)
Broadcom (AVGO)
JPMorgan Chase & Co. (JPM)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
State Str Spdr S&p 500 Etf T Tr Unit (SPY)
Vanguard Charlotte Fds Total Int Bd Etf (BNDX)
Johnson & Johnson (JNJ)

View all positions for Wiley Bros.-aintree Capital

Top funds holding Bioxcel Therapeutics

Millennium Management
Armistice Capital
Vanguard Group
Oaktree Capital Management
Geode Capital Management
Vanguard Capital Management
Jones Financial Companies, L.L
Man Group
State Street Corporation
FMR
Vanguard Fiduciary Trust
BlackRock
Wiley Bros.-aintree Capital
UBS Group
Oaktree Fund Advisors

View all funds holding Bioxcel Therapeutics